Find out more about the NICE Diagnostics Advisory Committee members by reading their biographies.
Professor Adrian Newland CBE
Professor Newland has been a Consultant Haematologist at Barts and the London NHS Trust for almost 30 years, and Professor of Haematology at Queen Mary's School of Medicine and Dentistry (Barts and the London), since 1995. He is Director of Pathology for the Trust. He took up the position as Chair having already held a number of high-profile positions, including President of the Royal College of Pathologists (2005 - 2008), and Director of the North East Thames Cancer Network (2001 - 2013), amongst many others.
He is currently chair of the Healthcare Forum of the UK Accreditation Service, Pathology Diagnostic Advisor to NHS England (London) and also Vice-Chair of the national Chemotherapy Clinical Reference. Professor Newland also chaired the London Cancer New Drugs Group, which has a remit to review drugs that have not yet been through the NICE assessment process and currently runs the Cancer Drug Fund in London.
Mr John Bagshaw
In-Vitro Diagnostics Consultant
Dr Philip Chambers PhD, MSc, BSc
Research Fellow, Leeds Institute of Cancer & Pathology
Dr Sue Crawford MRCP, MRCGP, DipRCPath
General Practitioner in Devon
Dr Sue Crawford is a general practitioner with an interest in diagnostics and in improving the primary / secondary care working interface.
She has been a partner in a rural dispensing practice in the South Hams for the last 3 years.
During this time she has established the practice as part of the Primary Care Research Network. For 10 years prior to moving to Devon she combined roles as an Associate Specialist in Haematology in West Dorset with being an assistant to a single handed rural GP and GP educator for the Dorset GP training scheme. She now represents the practice on the local commissioning consortium.
Professor Erika Denton FRCP, FRCR
National Clinical Director for Diagnostics, NHS England
Erika was appointed to the role of National Clinical Director for Diagnostics in spring 2013. From 2005-2013 Erika was National Clinical Lead, and subsequently National Clinical Director, for Imaging at DH leading a complex programme of work across all aspects of imaging. This work delivered considerable additional capacity for imaging services and marked reduction in waiting times. Her work has included delivering significant improvements in Cancer, Paediatric, Interventional, Cardiac and Forensic imaging services. In her roles in Connecting for Health she has led deployment of PACS systems across the NHS and is now leading the process to move PACS to local NHS ownership.
Erika was previously Divisional Clinical Director for support services, Director of Breast Screening and head of radiology training in Norwich. She continues to practice clinically 2 days a week and to publish in breast imaging and health care policy.
Dr Steve Edwards BSc (Hons), MSc, DPhil
Head of Clinical and Economic Evidence, BMJ-TAG, BMJ
For more than 15 years Steve has conducted systematic reviews and health economic evaluations in a range of therapeutic areas including cardiovascular, CNS, gastroenterology, infection, oncology, and respiratory medicine. He currently leads a technology assessment group, based at the BMJ, which supports the NICE Technology Appraisal Programme.
He is also an Honorary Lecturer in Public Health at the London School of Hygiene and Tropical Medicine, a member of the Cochrane Pregnancy & Childbirth Group, and the statistics advisor for diagnostic test accuracy systematic reviews for the Cochrane Skin Group.
Dr Simon Fleming MSc, MD, FRCPath
Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Cornwall Hospital
Simon Fleming is a Consultant in Clinical Biochemistry and Metabolic Medicine in Cornwall and Honorary Teacher at the Peninsula College of Medicine and Dentistry. He trained in London and Newcastle upon Tyne and has specialist interests in lipidology, diabetes, clinical nutrition and cardiovascular research.
He has previously worked as a reviewer for National Confidential Enquiry into Patient Outcome and Death (NCEPOD) and the HTA Diagnostics Programme.
Dr James William Gray
Consultant Microbiologist, Department of Microbiology, Birmingham Children’s Hospital
Jim Gray has been a Consultant Microbiologist at Birmingham Children’s and Women’s Hospitals since 1995. Clinical and research interests include diagnostic test accuracy studies and improving the laboratory-clinical interface, in particular to ensure that key laboratory results are reported and appropriately acted upon without delay.
Recent service innovations include introduction of Advance Laboratory Practitioners, multidisciplinary laboratory working to support infection control and antibiotic decision making on an out of hours basis. Research interests include point of care testing for group B streptococcus screening in labouring women and improved blood culture technology to support antibiotic stewardship in neonates.
Jim has worked on several NICE Programmes, including being a member of two Guideline Development Groups and a Standing Member of a Rapid Clinical Guideline Updates Committee. He is an Expert Advisor for the British National Formulary for Children (BNF-C), and has served on a number of national committees relating to paediatric infectious diseases and antibiotic treatment. He is Editor-in-Chief of The Journal of Hospital Infection and an Assistant Editor of International Journal of Antimicrobial Agents and the Journal of Pediatric Infectious Diseases.
Mr John Hitchman
John Hitchman is a retired Chartered Architect who was Principal of a private practice in Co. Durham. He has served on standard committees for a number of statutory and voluntary organisations and currently sits on the Lord Chancellor's Advisory Committee for the Selection of Magistrates. John is a member of the Lay Group of the Royal College of Anaesthetists where he serves on a range of the College's committees. He is also the lay representative on Peer Review Panels for the Association of Paediatric Anaesthetists of Great Britain and Ireland. John's particular interest in the NHS is the improvement of the patient experience especially for the young and the vulnerable.
Professor Chris Hyde
Professor of Public Health & Clinical Epidemiology, Peninsula College of Medicine and Dentistry
Chris Hyde trained in medicine and public health in London and East Anglia respectively. His expertise is in systematic reviews and health technology assessments, particularly in the context of providing support to policy-makers. In this respect he has undertaken many reports for NICE, particularly its Technology Appraisal Programme.
During his career he has set up and directed the Aggressive Research Intelligence Facility (ARIF), an effectiveness information support service for commissioners in the West Midlands. Chris has also directed the West Midlands Health Technology Assessment Collaboration and been closely involved with the Systematic Reviews Initiative of the National Blood Service. He has long-standing connections with the Cochrane Collaboration and is an editor of the NHS HTA Monograph series. He is currently based at the Peninsula College of Medicine and Dentistry where he leads the Technology Appraisal Group in PenTAG.
He has a long-standing interest in the evaluation of tests and has done health technology assessments on many topics including automated cervical screening, hysteroscopy, prediction of pre-eclampsia and pre-term birth, PET/CT, orthopantomography and identifying genetic sub-types in diabetes. He is currently part of the UK Support Unit for Cochrane Diagnostic Test Accuracy Reviews based at the University of Birmingham; and a member of the Cochrane Diagnostics Test Accuracy Editorial Board.
Dr Mark Kroese MB, ChB, DPH, FFPH, FRCP(Ed), MRCGP
Consultant in Public Health Medicine, PHG Foundation, Cambridge and UK Genetic Testing Network
Mark Kroese is a Consultant in Public Health Medicine at the PHG Foundation, Cambridge and was appointed Public Health Advisor to the UK Genetic Testing Network in 2006. Prior to joining the PHG Foundation, Mark worked for nearly 7 years as Consultant in Public Health Medicine at Peterborough Primary Care Trust.
His specialist interests are in the evaluation and regulation of genetic tests and the commissioning of clinical genetics services.
Mr Patrick McGinley ICMA, CGMA
Head of Costing and Service Line Reporting, Maidstone and Tunbridge Wells NHS Trust
Patrick started as a Trainee Accountant at St Bartholomew’s Hospital in 1983, and apart from a brief sojourn to the far NW of Scotland as a postmaster, has worked in the NHS ever since in a variety of roles and institutions including at the Royal London, Homerton, Whipps Cross and Great Ormond Street before moving to Maidstone & Tunbridge Wells
He is currently Head of Costing and SLR, and has implemented an automated system of calculating costs at a patient level, and firmly believes that improved costing can help the NHS to understand its business, and maximise the value of healthcare.
He has direct operational experience as a Programme Manager of an NHS Breast Screening Unit, to go with experience as a Management and Costing Accountant, and he has successfully completed two PFI projects (BLT and TWH) as financial lead to offset the significant number of hospitals that he has helped to shut over his career.
He is an active member of the HFMA Costing Special Interest Group, and is also a member of NHSI’s Costing Advisory Group and technical review group, is a reviewer for both NICE and NIHR, and has presented regularly at National events on Acute Costing Standards.
He was a member of tariff calculation groups for NCAT for Chemotherapy and Radiotherapy, is a Fellow of Royal Statistical Society and a member of HSUG. He lectures on statistics for journalists for RSS. He benchmarks costing approaches with international colleagues, and is a training mentor for Chartered Institute of Management Accountants; understandably, he is therefore rarely allowed out on his own.
Dr Michael Messenger
Deputy Director and Scientific Manager - NIHR Diagnostic Evidence Co-operative Leeds
Dr Michael Messenger is the Deputy Director and Scientific Manager for the NIHR Diagnostic Evidence Co-Operative Leeds and is responsible for overseeing the delivery of high quality scientific evidence on in-vitro diagnostics (IVD) for the NHS.
As the Principal Healthcare Scientist on a NIHR Applied Programme Grant for Research “Evaluating the benefits for patients and the NHS of new and existing biological fluid biomarkers in liver and renal disease” he has experience across many phases of the “diagnostic pipeline” including the development, validation and clinical evaluation of new diagnostic assays.
Mrs Alexandria Moseley
Alexandria holds a degree in International Finance from the Wharton School as well as a degree in product design from FIT in New York City. She has been a Wall Street trader, serial entrepreneur, business owner, industry consultant, lifestyle blogger, and health advocate.
Served for many years as an international lay reviewer for Juvenile Diabetes Research Foundation and as a member of the Diabetes Research Network, plus one year on the Lay Committee for Diabetes UK. Invited as a patient expert for two previous NICE committees formulating guidance on insulin pumps. She has a special interest in autoimmune diseases.
Dr Peter Naylor
General Practitioner, Chair Wirral Health Commissioning Consortia
Dr Pete Naylor is a General Practitioner in Wallasey, Wirral where he has been for 14 years. Over many of these years he has been involved in healthcare management and is now Assistant Clinical Chair to Wirral Clinical Commissioning Group and Chair of Wirral Health Commissioning Consortium.
He has particular interests in integrated working, quality, engagement and the appropriate development of telehealth technologies. He admits to a core drive to the reduction of health inequalities and this is a problem he particularly faces in his local area.
Dr Dermot Neely BSc, MD, FRCP, FRCPath
Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Victoria Infirmary, Newcastle Upon Tyne
Dermot Neely is a Consultant in Clinical Biochemistry and Metabolic Medicine in Newcastle Upon Tyne Hospitals NHS Trust and Associate Clinical Lecturer at the University of Newcastle. He trained in Belfast and has specialist interests in lipidology and cardiovascular research. He is Director of the Newcastle Supra-Regional Assay Service (SAS) Cardiovascular Biomarkers and Endocrine Laboratories and is Lead for Evaluation for the Newcastle NIHR Diagnostic Evidence Co-operative.
He has previously served as a member of the Guideline Development Group for the NICE Lipid Modification Guideline (CG67) Review and as a reviewer for the HTA Diagnostics Programme.
Dr Simon Richards PhD
VP, Regulatory Affairs, EME, Alere
Simon Richards is VP, regulatory Affairs EME for Alere. Originally a Ph.D Biochemist working on chemiluminescent assay techniques, he has worked in the Vaccines and Diagnostics industry for over 20 years. He began his career at Amersham/ Johnson+Johnson as a scientist before transitioning into Quality and Regulatory roles of increasing seniority in DPC (now part of Siemens), Novartis, Axis-Shield and now Alere.
He is also the chair of the Regulatory Affairs Working party for the UK IVD Industry body, BIVDA.
Dr Deirdre Ryan MB, BCh, BAO, FRCPath
Consultant Cellular Pathologist, Barts Health NHS Trust
Dr Deirdre Ryan is a consultant Pathologist at Barts Health NHS trust. A graduate of University College Dublin, she began her pathology training in Ireland before moving to London to continue this training. She was appointed as an NHS consultant in 2001. Her area of specialist interest is breast cancer and she has been Lead for Breast Pathology since 2007. She is also Clinical Lead for Cellular Pathology at Barts Health NHS Trust since 2013.
Professor Mark Sculpher BA (Hons), MSc, PhD
Professor of Health Economics, Centre for Health Economics, University of York
Mark Sculpher has worked in the field of economic evaluation and health technology assessment for over 25 years. He has researched in a range of clinical areas including heart disease and cancer, and evaluated therapeutic and diagnostic technologies He has also contributed to methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty. He has over 200 peer-reviewed publications and is a co-author of two major text books in the area.
Mark is a member of the UK National Institute of Health Research (NIHR) College of Senior Investigators. He has also been a member of the NICE Technology Appraisal and Public Health Interventions Advisory Committees. He chaired NICE's 2004 Task Group on methods guidance for economic evaluation; and has also advised health systems internationally on HTA methods including those in Ireland, Portugal, France and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme and currently sits on the UK Medical Research Council's Methodology Research Panel.
Professor Matt Stevenson BSc, PhD
Director of the School of Health and Related Research Technology Assessment Group
Matt studied Operational Research at Lancaster University where he received his doctorate. He worked for the University of Sheffield for over 20 years, during which time he conducted cost-effectiveness analyses primarily for the National Institute for Health Research.
Matt is Director of the School of Health and Related Research Technology Assessment Group, an academic group undertaking modelling work to provide data for NICE technology and diagnostic appraisals. He is also a member of our technology appraisal committee, as well as our decision support unit.
Dr Steve Thomas MBBS, MRCP, FRCR, MSc
Consultant Vascular and Cardiac Radiologist at Sheffield Teaching Hospitals Foundation Trust.
Steve Thomas is a Consultant Cardiovascular Radiologist with expertise in diagnostic and interventional vascular radiology, and non- invasive assessment of cardiac disease using Cardiac Magnetic Resonance imaging and Computed Tomography.
He is an Honorary Clinical Senior Lecturer at the University of Sheffield, where he has been carrying out Health Economic and Technology Appraisal research into new techniques/ technologies and diagnostics relevant to his clinical work.
Professor Anthony Wierzbicki BA, MA, BM, BCh, DPhil, DM
Consultant in Metabolic/Chemical Pathology, St Thomas Hospital
Professor Anthony Wierzbicki is consultant in metabolic medicine & chemical pathology and has been director of the lipid unit at St. Thomas and Guy’s Hospitals in 1994. His work in the field of atherosclerosis has led to appointments as a Fellow of National Association of Clinical Biochemistry (USA) and the American Heart Association (arteriosclerosis and blood pressure sections). He has been a trustee of HEART-UK (the UK cholesterol charity) and chairman of this charity’s medical and scientific committee. His clinical interests are in diagnostics, cardiovascular risk quantification systems and the molecular genetics of hyperlipidaemia. He is a member of the SE London cardiac network treatment and vascular risk guideline groups. He was a member of the writing group of the International Familial Hypercholesterolaemia guidelines. He has served at NICE on Technology Appraisal panels, the familial hypercholesterolaemia guideline group (CG71) and chaired the Lipids and Cardiovascular risk assessment guideline (CG181).